An acute asthma exacerbation is a deterioration in baseline symptoms or lung function requiring a change in treatment, ranging from mild episodes manageable with rescue therapy to life-threatening events requiring intubation. [1-2] The following is a comprehensive clinical summary organized for emergency medicine and primary care workflows.
The following figure from the AAFP outlines the ED management algorithm for acute asthma exacerbations:
1. History
- Onset and progression: Acute vs. subacute worsening; hours to days of increasing dyspnea, cough, wheezing, chest tightness [2]
- Triggers: Viral URI (most common), allergen exposure, air pollution, exercise, cold air, medication non-adherence, NSAID/aspirin/beta-blocker use [1][3-4]
- Severity markers: Ability to speak in full sentences vs. words/phrases, ability to lie flat, sleep disruption, rescue inhaler frequency [2]
- Medication history: Current controller regimen, SABA use in past 24 hours (>8 puffs is a red flag), recent OCS use, adherence to ICS [2][5]
- Prior exacerbation history: Previous intubation, ICU admission, ED visits, hospitalizations in the past year [4][6]
- Important negatives: Fever (suggests infection or alternative diagnosis), unilateral wheeze (foreign body, mucus plug), leg swelling/pleuritic pain (PE), orthopnea with peripheral edema (CHF) [1][4][7]
2. Alarm Features
- Drowsiness, confusion, or altered mental status — cerebral hypoxemia, impending respiratory failure [4][6]
- Silent chest — minimal ventilation insufficient to produce wheeze [4][6]
- Inability to speak or complete sentences [2]
- SpO₂ <90% on room air — signals need for aggressive therapy [4-5]
- SpO₂ <92% — associated with high morbidity and likely need for hospitalization [4-5]
- Paradoxical chest/abdominal movement [8]
- Cyanosis [6]
- PEF or FEV₁ <25% predicted pre-treatment [4-5]
- Normal or rising PaCO₂ (≥40 mmHg) during exacerbation — indicates fatigue and impending respiratory failure [5-6]
- No improvement with standard treatment — consider asthma mimics [7]
3. Medications
Acute treatment (per GINA 2025 and AAFP): [1-2][6]
- Albuterol (SABA): Adults — 2.5–5 mg nebulized q20min × 3 doses, then 2.5–10 mg q1–4h PRN; or 4–10 puffs MDI with spacer q20min × 3. Children — 0.15 mg/kg (min 2.5 mg) nebulized q20min × 3 [2]
- Ipratropium bromide: Adults — 0.5 mg nebulized q20min × 3 doses; Children — 0.25–0.5 mg q20min × 3 doses. Add for moderate-severe exacerbations; associated with fewer hospitalizations [2][6]
- Systemic corticosteroids (within first hour): Adults — prednisone/prednisolone 40–50 mg PO daily × 5–7 days; Children — 1–2 mg/kg/day (max 40 mg) × 3–5 days; or dexamethasone 0.3–0.6 mg/kg/day × 1–2 days [1-2][6]
- IV magnesium sulfate: 2 g IV over 20 min (adults) for severe exacerbations not responding to initial therapy; children 40–50 mg/kg (max 2 g) [2][5]
- Epinephrine IM: Only for anaphylaxis or angioedema-associated bronchospasm [2]
- High-dose ICS: ≥2 mg beclomethasone equivalent within first hour may reduce hospitalizations [2]
Medications to avoid/use with caution
- Beta-blockers (including ophthalmic) — can precipitate severe bronchospasm
- NSAIDs/aspirin — in aspirin-exacerbated respiratory disease (AERD)
- Sedatives — contraindicated during acute exacerbation (mask respiratory failure)
- Routine antibiotics — not recommended unless clear bacterial infection [5-6]
4. Diet
- Hydration: Encourage adequate oral hydration; dehydration can thicken secretions
- Confirmed food allergy: Patients with asthma and food allergy are at increased risk of fatal/near-fatal exacerbations [4][6]
- Long-term: Mediterranean diet and diets rich in fruits, vegetables, and omega-3 fatty acids may have modest anti-inflammatory benefit; obesity is a modifiable risk factor [5]
5. Review of Systems
- Pulmonary: Dyspnea, cough (productive vs. dry), wheeze, chest tightness, exercise tolerance
- ENT: Nasal congestion, postnasal drip, sinus pressure (rhinosinusitis is a common comorbidity) [4-5]
- GI: Heartburn, regurgitation (GERD worsens asthma) [5]
- Cardiac: Palpitations, chest pain, orthopnea, lower extremity edema (rule out CHF) [4][7]
- Psych: Anxiety, panic symptoms (can mimic or worsen dyspnea perception)
- Constitutional: Fever (infection vs. alternative diagnosis), weight changes (obesity)
6. Collateral History and Family History
- Collateral: Medication adherence, inhaler technique, home environment (mold, pets, smoke exposure), written asthma action plan availability [4]
- Family history: Asthma, atopy (eczema, allergic rhinitis, food allergy), family history of asthma-related death
- Social context: Socioeconomic status, access to medications, housing conditions, smoking/vaping in household, psychological stressors — all independently associated with exacerbation risk [5-6]
7. Risk Factors
For exacerbation: [5-6]
- Uncontrolled asthma symptoms
- SABA overuse (≥3 × 200-dose canisters/year; mortality increases if ≥1 canister/month)
- Inadequate ICS (not prescribed, poor adherence, incorrect technique)
- ≥1 severe exacerbation in the past year
- Low FEV₁ (especially <60% predicted)
- Obesity, chronic rhinosinusitis, GERD, confirmed food allergy
- Smoking, e-cigarettes, allergen/pollution exposure
- Major psychological or socioeconomic problems
For asthma-related death: [4][6]
- History of near-fatal asthma requiring intubation/mechanical ventilation
- Hospitalization or ED visit for asthma in the past year
- Currently using or recently stopped OCS
- Not currently using ICS
- SABA overuse (>1 canister/month)
- Psychiatric disease, psychosocial problems
- Food allergy in a patient with asthma
- Comorbid pneumonia, diabetes, arrhythmias
8. Differential Diagnosis
Cannot-miss diagnoses: [1][4][7]
- Anaphylaxis — urticaria, angioedema, hypotension, rapid onset
- Foreign body aspiration — unilateral wheeze, sudden onset, especially in children/elderly
- Pulmonary embolism — pleuritic pain, tachycardia, risk factors for VTE
- Tension pneumothorax — unilateral absent breath sounds, tracheal deviation
- Cardiac tamponade/acute heart failure — JVD, peripheral edema, S3 gallop
Common mimics: [4][7]
- COPD exacerbation — smoking history, older age, less reversibility
- Vocal cord dysfunction (inducible laryngeal obstruction) — inspiratory stridor, no response to bronchodilators, flattened inspiratory loop on flow-volume curve
- Heart failure — orthopnea, BNP elevation, bilateral crackles
- Upper airway cough syndrome (postnasal drip) — throat clearing, nasal congestion
- GERD — nocturnal cough, heartburn
- Panic attack/hyperventilation — perioral tingling, carpopedal spasm, normal SpO₂
Red flags for misdiagnosis: No prior asthma history, mild asthma presenting with severe symptoms, no improvement with standard therapy [7]
9. Past Medical History
- Prior asthma diagnosis, age of onset, baseline severity classification
- Previous intubations, ICU admissions, hospitalizations (strongest predictor of future near-fatal events) [6]
- Frequency of ED visits and OCS courses in the past year
- Atopic comorbidities: eczema, allergic rhinitis, nasal polyps (consider AERD triad)
- Comorbidities: obesity, GERD, OSA, chronic rhinosinusitis, anxiety/depression [5]
- Surgical history: prior sinus surgery, prior thoracic procedures
10. Physical Exam
Vital signs: [2]
- Tachypnea, tachycardia (also from albuterol)
- Pulsus paradoxus >12 mmHg suggests severe obstruction
- SpO₂ <92% on room air — high morbidity marker
Focused exam
- Lungs: Diffuse expiratory wheezing; silent chest is ominous (insufficient airflow to generate wheeze) [4]
- Accessory muscle use: Sternocleidomastoid, intercostal, subcostal retractions
- Speech: Full sentences (mild) → phrases (moderate) → words only (severe) [2]
- Position: Tripoding, inability to lie flat
- Skin: Diaphoresis, cyanosis (late finding)
- ENT: Nasal polyps, turbinate edema (allergic rhinitis)
- Cardiac: Assess for S3, JVD, peripheral edema (rule out CHF)
11. Lab Studies
Labs are not routinely required but should be obtained selectively: [4-6][8]
- Pulse oximetry: Continuous monitoring; SpO₂ <92% predicts hospitalization. Note: may overestimate in patients with dark skin color [5-6]
- VBG/ABG: Consider if PEF/FEV₁ <50% predicted or clinical deterioration. A normal or rising PaCO₂ (≥40 mmHg) during an exacerbation is a danger sign indicating respiratory muscle fatigue. PaO₂ <60 mmHg with PaCO₂ >45 mmHg = respiratory failure [5-6]
- CBC: If infection suspected (leukocytosis may also be steroid-induced)
- BMP: Hypokalemia and hypomagnesemia from repeated albuterol; monitor potassium
- BNP: If CHF is in the differential [9]
- Troponin: Consider in older adults or those with cardiac risk factors; troponin elevation can occur with continuous albuterol [10]
- Procalcitonin: May help differentiate bacterial infection if antibiotics are being considered [9]
- Lactate: If sepsis or severe hypoperfusion is suspected
12. Imaging
- Chest X-ray: Not routinely recommended. Consider if: [5-6]
- Suspicion for pneumothorax, pneumomediastinum, pneumonia, or foreign body
- Failure to respond to standard treatment
- Fever with localized findings
- Older adults (to exclude CHF, mass)
- CT chest: Rarely indicated acutely; consider CTA if PE is suspected
- POCUS: Useful bedside tool for ruling out pneumothorax, pleural effusion, assessing cardiac function, and evaluating for B-lines (pulmonary edema) [9]
13. Special Tests
- Peak expiratory flow (PEF) or FEV₁: Strongly recommended before and after treatment. Severity stratification: [2][4-5]
- Mild: PEF >70% predicted
- Moderate: PEF 40–69% predicted
- Severe: PEF <40% predicted
- Pediatric Asthma Score (PAS): Validated bedside scoring tool for children 2–18 years using respiratory rate, O₂ requirements, auscultation, retractions, and dyspnea (score 5–15) [4][6]
- PRAM and PASS: Scoring systems for younger children [4][6]
- End-tidal CO₂ (ETCO₂): Waveform capnography can track bronchospasm severity and response to treatment; rising ETCO₂ suggests worsening obstruction [9]
14. ECG
- Not routinely indicated but should be obtained if: [8-9]
- Cardiac disease is suspected (chest pain, palpitations, older adults)
- Continuous albuterol is being administered (can cause tachycardia, hypokalemia-related changes)
- Concern for PE (right heart strain pattern)
- Expected findings during exacerbation: Sinus tachycardia, right axis deviation, P-pulmonale, RV strain pattern
- Concerning findings: ST depression (24–30% of children on continuous albuterol had troponin elevation or ST changes in one study), new arrhythmia, signs of ischemia [10]
- Albuterol effects: Tachycardia, QTc prolongation (from hypokalemia), ST-T wave changes
15. Assessment
Severity stratification (NHLBI/GINA): [2][4-5]
Typical presentation: Progressive dyspnea, cough, and wheeze over hours to days, often triggered by URI or allergen exposure. Atypical presentations include cough-variant asthma (cough without wheeze), chest tightness only, or exercise-induced symptoms. [3]
Complications: Pneumothorax, pneumomediastinum, atelectasis (mucus plugging), respiratory failure, hypoxic brain injury, death. [6]
16. Treatment Plan
Initial stabilization (first 60 minutes): [1-2][6]
- ABCs — assess airway, breathing, circulation; prepare for intubation if life-threatening features present
- Oxygen: Target SpO₂ 93–95% in adults/adolescents (higher targets may worsen hypercapnia); ≥94% in children [2]
- Albuterol: 2.5–5 mg nebulized (or 4–10 puffs MDI + spacer) q20min × 3 doses
- Ipratropium: 0.5 mg nebulized q20min × 3 doses for moderate-severe exacerbations
- Systemic corticosteroids: Prednisone 40–50 mg PO (adults) or 1–2 mg/kg (children, max 40 mg) — give within the first hour
Escalation for severe/refractory cases: [1-2][6]
- IV magnesium sulfate: 2 g over 20 min (adults); 40–50 mg/kg (max 2 g) in children
- High-dose ICS: ≥2 mg beclomethasone equivalent in the first hour
- Continuous nebulized albuterol: 10–15 mg/hour for severe cases
- Epinephrine IM: Only if anaphylaxis or angioedema
- Non-invasive ventilation (NIV): May be considered in select patients as a bridge
- Intubation: For impending respiratory failure (drowsiness, rising PaCO₂, silent chest). Use ketamine for induction (bronchodilatory properties); avoid histamine-releasing agents
Post-acute/discharge management: [2]
- Prescribe or continue ICS (initiate before discharge if not already on one)
- OCS course: Adults — prednisone 50 mg/day × 5–7 days; Children — 1–2 mg/kg × 3–5 days (no taper needed for short courses)
- Review and provide a written asthma action plan [1][4]
- Assess and correct inhaler technique
- Consider step-up of controller therapy for 2–4 weeks
17. Disposition
Admit if: [2][4-6]
- Pre-treatment FEV₁/PEF <25% predicted
- Post-treatment FEV₁/PEF <40% predicted after 1 hour of treatment
- Persistent hypoxia (SpO₂ <92%) despite treatment
- Ongoing need for supplemental oxygen or frequent bronchodilators
- History of near-fatal asthma, prior intubation
- Inability to lie flat, persistent accessory muscle use
- Inadequate home support or inability to follow up
ICU admission: [2]
- Drowsiness, confusion, or altered mental status
- Silent chest
- Requiring intubation or NIV
- Hemodynamic instability
- PaO₂ <60 mmHg or PaCO₂ >45 mmHg despite treatment
Discharge criteria: [2][4-5]
- Symptom improvement with sustained response
- Post-treatment PEF/FEV₁ >60% predicted (ideally 60–80%)
- SpO₂ >94% on room air
- Able to use inhaler correctly
- Has access to medications and follow-up
- Adequate home support and understanding of action plan
Observation: Post-treatment PEF 40–60% predicted — discharge may be possible depending on risk factors and follow-up availability [4-5]
18. Follow Up / Return Precautions
Follow-up timing: [2]
- Adults/adolescents: 2–7 days after ED discharge
- Children: 1–2 working days
- Reassess at 1–3 months to confirm improvement and consider step-down
Return precautions — instruct patients to seek immediate care if:
- Worsening shortness of breath or inability to speak in full sentences
- No relief from rescue inhaler within 15–20 minutes
- Needing rescue inhaler more frequently than every 4 hours
- Lips or fingernails turning blue
- Drowsiness or confusion
- Chest pain
Patient counseling: [1-2][4]
- Emphasize adherence to ICS controller therapy — the single most important modifiable factor
- Review and reinforce written asthma action plan
- Demonstrate proper inhaler/spacer technique
- Avoid identified triggers (allergens, smoke, pollution)
- Influenza and COVID-19 vaccination
- Smoking/vaping cessation
- Follow up with PCP or pulmonologist for long-term management optimization
Expected recovery: Most patients improve significantly within 1–2 hours of aggressive treatment. Full recovery from an exacerbation typically takes 7–14 days, during which airway hyperreactivity remains elevated and patients are vulnerable to re-exacerbation. [1][3]
References
1. 2024 Summary Guide for Asthma Management and Prevention. — Helen Reddel, Arzu Yorgancioglu, Mark L. Levy, Rebecca Decker, Kristi Ruey Global Initiative for Asthma. 2024.
2. Acute Asthma Exacerbations: Management Strategies. — Dabbs W, Bradley MH, Chamberlin SM. American Family Physician. 2024.
3. Asthma. — Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Lancet. 2023.
4. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. — Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, et al Global Initiative for Asthma. 2023.
5. 2024 Global Strategy for Asthma Management and Prevention. — Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, et al Global Initiative for Asthma. 2024.
6. 2025 Global Strategy for Asthma Management and Prevention. — Helen Reddel, Eric Bateman, Gerard FitzGerald, et al Global Initiative for Asthma. 2025.
7. Clinical Mimics: An Emergency Medicine-Focused Review of Asthma Mimics. — Kann K, Long B, Koyfman A. The Journal of Emergency Medicine. 2017.
8. Emergency Treatment of Asthma. — Lazarus SC. The New England Journal of Medicine. 2010.
9. Acute Care of Patients With Moderate Respiratory Distress: Recommendations From an American College of Emergency Physicians Expert Panel. — Baugh CW, Neuenschwander JF, Lenox J, et al. The Western Journal of Emergency Medicine. 2025.
10. Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children. — Fagbuyi DB, Venkataraman S, Ralphe JC, et al. Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine. 2016.